Reynold Lemkins Group, a leading global investment firm focused on late-stage growth and frontier technologies, announced its significant cornerstone investment in the initial public offering (IPO) of Cloudbreak Pharma (02592.HK) on the Hong Kong Stock Exchange (HKEX). This strategic investment underscores Reynold Lemkins Group’s commitment to backing visionary biotech companies poised to deliver transformative solutions to global challenges.

Cloudbreak Pharma, a clinical-stage ophthalmic biotechnology company, recently completed its HKD 612 million growth-focused IPO. Focused on innovative therapies like CBT-001 for pterygium (in Phase 3 U.S./China trials and potentially the world's first approved non-surgical treatment), Cloudbreak Pharma will utilize proceeds to fund critical R&D, manufacturing expansion, and commercialization of its lead biologic assets. Reynold Lemkins Group served as a cornerstone investor, committing USD 22.8 million (HKD 179 million) to the offering alongside Wealth Strategy Holding, with collective cornerstone investment totaling approximately USD 45.6 million.

Reynold Lemkins Group’s role as a cornerstone investor in this HKEX listing further solidifies its position as a crucial cross-border capital partner. The firm leverages its deep expertise in navigating complex international markets to connect promising innovation from Asia with global investment, facilitating the growth of companies that are redefining industries worldwide. This strategic focus is underscored by the firm's consistent track record in the biotech sector, including its prior participation in the successful IPO of VISEN Pharmaceuticals (HKEX: 02561), which similarly attracted strong institutional demand and aligned with Reynold Lemkins’ commitment to regulatory-validated, commercially scalable businesses. This investment exemplifies Reynold Lemkins Group’s strategy of providing patient, strategic capital to ventures at the forefront of technological and medical advancement, ensuring their ability to scale and deliver.

"Cloudbreak Pharma epitomizes Reynold Lemkins Group's core philosophy: empowering companies that are truly transforming their fields," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "We're proud to back a biotech pioneer bringing life-changing science to global health. This investment perfectly aligns with our drive to bridge cross-border capital with transformative growth, creating lasting value."

To learn more, visit www.reynoldlemkins.com, follow us on LinkedIn, or explore our insights on Medium.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250804206049/en/

Reynold Lemkins Group serves as a cornerstone investor in Cloudbreak Pharma's HKEX IPO, reinforcing its commitment to bridging cross-border capital with transformative growth.